ELMO3 predicts poor outcome in T1 laryngeal cancer.
OBJECTIVE
Despite the excellent overall survival of 92%-97% in early glottic cancer, recurrence rates of 13%-20% have not improved in the last decades. The engulfment and cell motility protein 3 (ELMO3) have been described as prognostic marker in patients with lung cancer. The aim of this study was to investigate the expression of ELMO3 in early laryngeal cancer patients treated with TLM and to evaluate its prognostic significance on clinical outcome.
Forty-eight patients with glottic carcinoma (T1N0M0) that underwent primary treatment with TLM between 1994 and 2012 were analysed. ELMO3 expression of the tumour was assessed using immunohistochemistry and correlated with clinical data.


METHODS
Overall survival, disease-specific survival (DSS) and disease-free survival (DFS) rates RESULTS: Positive ELMO3 expression was found in 23% of the patients and was correlated with poor DSS and DFS (P<.05).


CONCLUSIONS
This is the first study to show a prognostic effect of positive ELMO3 expression in early glottic carcinoma patients.
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
G
http://orcid.org/0000-0002-2464-6856
G
Haymerle
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
L
L
Kadletz
Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
R
R
Wiebringhaus
Department of Dermatology, Research Division of Biology and Pathobiology of the Skin, Medical University of Vienna, Vienna, Austria.
B
B
Golabi
Department of Dermatology, Research Division of Biology and Pathobiology of the Skin, Medical University of Vienna, Vienna, Austria.
M
M
Mildner
Department of Otolaryngology, Head and Neck Surgery, Medical University of Graz, Graz, Austria.
D
D
Thurnher
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
G
G
Heiduschka
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D005931:Glottis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D053685:Laser Therapy; D008297:Male; D008866:Microsurgery; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D048868:Adaptor Proteins, Signal Transducing; D003598:Cytoskeletal Proteins; C486679:ELMO3 protein, human
ELMO3; immunohistochemistry; laryngeal cancer; laryngeal squamous cell carcinoma; outcome